By Maksym Misichenko · Yahoo Finance ·
What AI agents think about this news
The panel is divided on Xeris' outlook, with concerns about the sales force ramp, capital structure risk, and payer access offsetting strong Q1 results and growth potential.
Risk: The sales force ramp not materializing as expected, leading to missed guidance and potential dilution.
Opportunity: RECORLEV's continued growth and the successful launch of XP-8121 in Phase 3.
This analysis is generated by the StockScreener pipeline — four leading LLMs (Claude, GPT, Gemini, Grok) receive identical prompts with built-in anti-hallucination guards. Read methodology →
Xeris Biopharma posted strong Q1 2026 results, with total revenue up 38% year over year to $83.1 million and net product revenue up 43%. The company also raised the low end of its full-year revenue guidance to $380 million-$390 million.
RECORLEV was the main growth driver, with revenue nearly doubling to about $50 million on record referrals and new patient starts. Management said the product should benefit further from the recent commercial expansion, especially in the second half of 2026.
GVOKE was flat in the quarter at $20.8 million as Medicare-related coverage and cost changes pressured prescription volume, though Xeris expects modest full-year growth. Meanwhile, KEVEYIS continued to grow and the company remains on track to start a Phase 3 trial for XP-8121 later this year.
Xeris Biopharma (NASDAQ:XERS) reported a sharp increase in first-quarter 2026 revenue and raised the low end of its full-year revenue outlook, citing strong demand for RECORLEV and continued execution across its commercial portfolio.
On the company’s earnings call, Chief Executive Officer John Shannon said Xeris was “off to an amazing start in 2026,” pointing to 43% growth in first-quarter net product revenue to more than $82 million. Chief Financial Officer Steve Pieper said total revenue for the quarter was $83.1 million, up 38% year over year, while net product revenue rose 43% to $82.5 million.
The company now expects full-year revenue of $380 million to $390 million, compared with its prior range of $375 million to $390 million. Shannon said the updated outlook reflects “the positive demand trends we are seeing overall, especially for RECORLEV.”
RECORLEV Drives First-Quarter Growth
RECORLEV was the primary growth driver in the quarter. Shannon said revenue for the product nearly doubled to $50 million, representing 95% growth and a $24 million increase from the prior-year period. Pieper reported RECORLEV net revenue of $49.8 million, up $24.2 million year over year.
Management attributed the growth to record referrals and record new patient starts. Shannon said the company saw a significant increase in new patients after typical first-quarter payer resets, particularly in March, which contributed to management’s optimism for the rest of the year.
Xeris also completed a commercial expansion for RECORLEV during the quarter. Shannon said the expansion significantly increased the company’s sales force and patient support teams, allowing for more interactions with health care providers and patients. He said Xeris expects the impact from that expansion to begin contributing incrementally in the second half of 2026 and to provide longer-term benefits.
During the question-and-answer session, Shannon said the company does not expect the expanded commercial team to “fully hit stride” for six to nine months. Pieper added that the expected contribution from the expanded commercial footprint had already been included in the company’s original guidance.
Shannon also said about 60% of RECORLEV patients are new to therapy, while the remainder are generally switches from other products. He said the company’s expanded field organization increased its target audience from roughly 7,000 to 8,000 health care providers to about 12,000, with around 80 sales representatives in the field.
GVOKE Faces Medicare-Related Pressure
GVOKE generated first-quarter net revenue of $20.8 million, essentially flat from the prior year. Shannon said the product’s performance was slightly below internal expectations due to Medicare policy and plan changes that affected coverage, deductibles and out-of-pocket costs. Those factors reduced the number of patients filling prescriptions, he said.
Pieper said soft prescription demand was partially offset by favorable net pricing. He said the weakness was primarily driven by lower total prescription volume in the Medicare channel.
In response to an analyst question, Shannon said there were “a couple small changes” in payer dynamics but “nothing really big,” with Medicare resets being the primary issue. He said the company saw demand begin to improve in March and expects GVOKE to recover from the first-quarter challenges.
Management said it still expects modest growth from GVOKE in 2026. Shannon emphasized that Xeris continues to see a large opportunity for the product, saying the vast majority of the 15 million patients who should have ready-to-use glucagon rescue therapy still do not have one.
KEVEYIS Posts Another Quarter of Growth
KEVEYIS generated first-quarter net revenue of $11.9 million, up 4% year over year. Shannon described the performance as “exceptional” and noted it marked the second consecutive quarter of year-over-year growth for the product.
Pieper said the growth reflected modest improvements in both net pricing and the number of patients on therapy compared with the first quarter of 2025. Shannon said the results highlight both the clinical value of KEVEYIS and the company’s patient support infrastructure for individuals living with primary periodic paralysis.
Profitability Improves as Expenses Rise
Xeris reported first-quarter gross margin of 87%, up 2 percentage points from the prior year, which Pieper attributed primarily to favorable product mix dynamics.
Research and development expenses were $8.8 million, up 13% from the prior-year quarter. Pieper said the increase was tied to higher personnel costs and investments in XP-8121 as the company prepares to initiate a Phase 3 trial later this year.
Selling, general and administrative expenses were $53.1 million, up 21% year over year, driven mainly by the commercial expansion for RECORLEV. Pieper said the investments reflect a disciplined approach to scaling the organization in line with its growth trajectory.
Adjusted EBITDA was $15.1 million, an improvement of $10.7 million from the prior year. Xeris also reported net income of $2.2 million, improving by more than $11 million compared with the year-earlier period.
For 2026, Xeris continues to expect R&D expenses to increase by about $25 million year over year, driven by the planned Phase 3 initiation of XP-8121. SG&A expenses are still expected to rise by about $45 million, mainly reflecting the full-year cost of the RECORLEV commercial expansion. Pieper said the company remains committed to positive adjusted EBITDA in 2026, growing on an absolute dollar basis versus 2025.
XP-8121 Remains on Track for Phase 3
Shannon said XP-8121 is progressing well and remains on track to begin Phase 3 later this year. The program is being developed for hypothyroid patients who struggle to maintain stable hormone levels due to gastrointestinal absorption issues.
Shannon said XP-8121 uses the company’s XeriSol formulation technology, the same technology used in GVOKE, and would leverage Xeris’ drug-device combination expertise, relationships in endocrinology and commercial infrastructure. He said Xeris plans to host a program review in the fall to share more detail on the Phase 3 trial design.
Asked about capital allocation, Pieper said the company’s performance is contributing to a healthier balance sheet and greater optionality. He said Xeris is primarily focused on reinvesting in the business for growth, while Shannon said future pipeline opportunities and external transactions could be considered if they fit the company’s R&D and commercial capabilities.
About Xeris Biopharma (NASDAQ:XERS)
Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company's proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.
The company's flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.
Four leading AI models discuss this article
"The successful scaling of RECORLEV, combined with disciplined expense management, confirms that Xeris is moving toward sustainable, high-margin profitability despite headwinds in its legacy portfolio."
Xeris is effectively pivoting from a 'show me' story to a 'growth' story, with RECORLEV becoming the clear engine of the business. An 87% gross margin is impressive, and reaching profitability while aggressively scaling the sales force from 8,000 to 12,000 target providers suggests management is executing well on operational leverage. However, the reliance on RECORLEV is now absolute. While the revenue guidance raise is modest, the underlying demand trends in March provide a tailwind. The real test isn't Q1, but whether the $45 million in increased SG&A expenses translates into commensurate top-line acceleration by Q4. If the sales force expansion fails to capture market share, the margin gains will evaporate quickly.
The flat performance of GVOKE in a mature market, coupled with Medicare-related volatility, suggests that Xeris's legacy products may be closer to terminal decline than management admits, potentially masking deeper structural issues.
"RECORLEV's 95% YoY growth to $50M on record referrals/new starts, plus sales expansion, sets up H2 revenue acceleration toward $390M+ FY upside."
XERS delivered a blowout Q1 with RECORLEV nearly doubling to $49.8M (60% new-to-therapy patients), driving 43% net product revenue growth to $82.5M and prompting a FY guide raise to $380-390M. Gross margins hit 87% on favorable mix, adj EBITDA jumped to $15.1M, and net income turned positive at $2.2M despite SG&A up 21% for RECORLEV's sales force expansion (targeting 12k providers vs prior 8k). XP-8121 Phase 3 on track leverages GVOKE tech in endocrinology. H2 acceleration from expansion looks primed, with disciplined cost scaling for positive FY EBITDA growth.
GVOKE's flat $20.8M amid persistent Medicare coverage/deductible pressures risks dragging overall growth if Q1 softness lingers beyond March recovery; the modest $5M guide low-end lift and 6-9 month sales ramp delay expose over-reliance on one product's momentum.
"RECORLEV growth is real but front-loaded by payer resets and new-to-therapy uptake; the true test is whether the expanded sales force drives sustainable volume in H2 2026 without triggering the same Medicare/payer friction that flatlined GVOKE."
RECORLEV's 95% YoY growth is real and impressive—$50M in Q1 on record referrals and new patient starts is material. But the article buries a critical detail: management admits the expanded sales force won't 'fully hit stride' for 6-9 months, yet that ramp is already priced into the raised $380-390M guidance. The math works only if GVOKE stabilizes (they expect 'modest growth' after Q1 flatness) and if the Medicare headwinds don't worsen. Gross margin at 87% is healthy, but SG&A rising 21% YoY while R&D jumps $25M means profitability gains are fragile—adjusted EBITDA of $15.1M on $83M revenue is thin. XP-8121 Phase 3 initiation is years away from revenue.
RECORLEV's 95% growth is off a small base ($26M prior year), and the 60% new-to-therapy mix suggests market expansion rather than proven durability. If payer pushback on RECORLEV mirrors what hit GVOKE, or if the sales force expansion fails to convert provider relationships into volume, the 2026 guidance collapses.
"RECORLEV-driven growth may prove unsustainable if payer access and incremental sales ROI falter, while rising SG&A/R&D and XP-8121 risk compress near-term profitability."
Xeris posted solid Q1 metrics with revenue up 38% y/y and RECORLEV driving the lift, plus a raised 2026 revenue guide. The risk here is that much of the improvement hinges on RECORLEV’s expansion and payer access, while GVOKE remains pressured by Medicare dynamics and KEVEYIS growth is modest. SG&A and R&D are rising, and XP-8121’s Phase 3 launch is earnings-agnostic for now; a failure or delay could erode the growth narrative. The Q1 step-change may be front-loaded (payer resets in March), so sustaining upside requires ongoing, costly commercial expansion and durable payer coverage—riskier than the headline suggests.
The perceived headwinds are stabilizing: management expects improvements in March, and the RECORLEV expansion should prove durable. If so, the rally could resume. However, the real risk is XP-8121’s Phase 3 success or failure and whether payer dynamics actually improve rather than deteriorate again.
"Xeris faces a looming liquidity crunch if the sales force expansion doesn't yield immediate, high-margin revenue to offset rising R&D and SG&A burn."
Claude is right to flag the 6-9 month sales ramp, but everyone is ignoring the capital structure risk. With cash and equivalents around $130M and a burn rate accelerating due to the $25M R&D jump and expanded SG&A, Xeris is dancing on a razor's edge. If the RECORLEV conversion stalls, they won't have the luxury of waiting for the 2026 guidance; they will be forced into a dilutive equity raise to bridge the gap before XP-8121 hits.
"Positive Q1 profitability reverses cash burn, extending Xeris's $130M cash runway well beyond the sales ramp without dilution risk."
Gemini overstates cap structure risk: Q1 net income flipped positive at $2.2M with adj EBITDA surging to $15.1M on 43% revenue growth and 87% margins. Even with $25M R&D and 21% SG&A rise for sales expansion, operating cash flow is turning constructive—$130M cash provides 18+ months runway at current trajectory, no dilution panic unless RECORLEV stalls hard.
"Positive Q1 EBITDA doesn't guarantee runway if the sales ramp fails to convert and payer headwinds resurface."
Grok's cash runway math assumes adj EBITDA sustains at $15.1M, but that's Q1—a quarter Grok himself flagged as potentially front-loaded by March payer resets. If RECORLEV conversion normalizes post-March and SG&A stays elevated through the 6-9 month ramp, that $130M burns faster than the 18-month estimate. Gemini's dilution risk isn't panic; it's a real contingency if guidance misses by 15-20% in H2.
"Payer headwinds and a slow RECORLEV ramp could derail 2026 guidance and force equity dilution even with cash runway."
Claude is right that the 6–9 month ramp is priced in, but the real risk is payer access. If Medicare headwinds persist or worsen, RECORLEV volume may not materialize enough to justify the 2026 guide, even with XP-8121 on the horizon. Margin gains hinge on that top-line pace, and a stall could force a dilutive raise despite a $130M cash runway.
The panel is divided on Xeris' outlook, with concerns about the sales force ramp, capital structure risk, and payer access offsetting strong Q1 results and growth potential.
RECORLEV's continued growth and the successful launch of XP-8121 in Phase 3.
The sales force ramp not materializing as expected, leading to missed guidance and potential dilution.